Figure 5.

Clinical relevance of combined BCAR4 and ERBB2 status. Expression of BCAR4 and ERBB2 mRNA levels was measured in a cohort of primary breast carcinomas. Patients were stratified according to the combined BCAR4 and ERBB2 status as indicated. BCAR4 was divided in negative (no call), and positive low and high by the mean. There is no relation observed between BCAR4 and ERBB2 expression. (A) Prevalence of breast tumours expressing BCAR4 and low levels of ERBB2. Number of tumours and percentages are shown for each group. (B) Progression-free survival of patients with ER-positive breast cancer who received first-line tamoxifen monotherapy for recurrent breast cancer. Patients with ERBB2-high tumours were grouped irrespective of their BCAR4 status. The patients at-risk at 12-month intervals are indicated. Abbreviations: neg=negative, pos=positive.